PTHS

Pelthos Therapeutics Inc. (PTHS) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Pelthos Therapeutics Inc. is a bio-pharmaceutical company formed effectively on July 1, 2025, via a merger between Channel Therapeutics Corporation and LNHC, Inc. The company commercializes ZELSUVMI (berdazimer topical gel), an FDA-approved treatment for molluscum contagiosum, launched in July 2025. It also holds clinical-stage assets targeting the NaV1.7 pain receptor. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics (Nine Months Ended Sept 30, 2025)

Note: Revenue and operating expenses for the nine-month period are driven almost entirely by the post-merger operations of LNHC (July 1–Sept 30, 2025), as the company had no commercial product prior to the merger.

Material Changes vs. Prior Period

• Revenue Generation: The company generated $7.4 million in revenue for the nine months ended Sept 30, 2025, compared to $0 in the same period in 2024. This is attributable to the commercial launch of ZELSUVMI.
• Operating Expenses: Total operating expenses surged to $27.8 million (9M 2025) from $5.7 million (9M 2024). This increase is primarily due to the inclusion of LNHC's commercialization costs, SG&A expenses related to the sales force launch, and amortization of intangible assets ($0.7 million) acquired in the merger.
• Balance Sheet Transformation: Total assets increased from $1.4 million (Dec 31, 2024) to $126.4 million (Sept 30, 2025). This reflects the acquisition of LNHC, which added $30.6 million in goodwill, $32.5 million in intangible assets, and $24.1 million in inventory.
• Liquidity: Cash balances increased from $0.5 million to $14.2 million, driven by a PIPE financing of approximately $27.4 million in net proceeds during the quarter.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next twelve months. Despite the recent cash infusion, the company expects to incur significant losses due to commercialization costs and requires additional capital.
• Subsequent Events (Nov 2025):
  • Convertible Note Financing: On Nov 6, 2025, the company raised $18 million in senior secured convertible notes.
  • Xepi Acquisition: The company entered an agreement to acquire Xepi (ozenoxacin cream) assets from Biofrontera for up to $10 million.
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting, citing a lack of segregation of duties, insufficient review levels, and inadequate IT infrastructure.
• Legal Proceedings: The company obtained a default judgment in its favor against a former executive (Mr. Kopfli) for approximately $18.3 million in damages. A separate demand letter from a former CMO was settled without payment of liquidated damages.

Investor Verification Checklist

• Capital Runway: Verify the sufficiency of the $14.2 million cash balance against the projected burn rate for ZELSUVMI commercialization and the $18 million debt service obligations from the November 2025 financing.
• Revenue Sustainability: Assess the concentration risk, as three wholesalers accounted for >94% of accounts receivable, and monitor the impact of co-pay assistance and rebates on net revenue.
• Debt Structure: Review the terms of the Reedy Creek liability ($20.3 million carrying value) and the new November 2025 convertible notes, including royalty obligations and conversion triggers.
• Internal Controls: Monitor the remediation plan for the identified material weaknesses in financial reporting and IT general controls.
• Merger Integration: Evaluate the progress of integrating LNHC's operations and the realization of synergies from the July 2025 merger.